Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION:
mipomersen shows promise as an adjunctive agent by reducing apoB-containing lipoproteins in patients at high risk of atherosclerotic cardiovascular disease who are not at target or are intolerant of statins. Although the short-term efficacy and safety of mipomersen has been established, concern exists regarding the long-term potential for hepatic steatosis with this ASO.
|
Authors | Damon A Bell, Amanda J Hooper, John R Burnett |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 20
Issue 2
Pg. 265-72
(Feb 2011)
ISSN: 1744-7658 [Electronic] England |
PMID | 21210756
(Publication Type: Journal Article, Review)
|
Chemical References |
- Apolipoprotein B-100
- Cholesterol, LDL
- Oligonucleotides
- Oligonucleotides, Antisense
- mipomersen
|
Topics |
- Apolipoprotein B-100
(biosynthesis, blood, genetics)
- Cholesterol, LDL
(blood, metabolism)
- Clinical Trials as Topic
- Dose-Response Relationship, Drug
- Humans
- Hypercholesterolemia
(drug therapy)
- Hyperlipidemias
(drug therapy)
- Hyperlipoproteinemia Type II
(blood, drug therapy)
- Molecular Targeted Therapy
- Oligonucleotides
(chemistry, metabolism, pharmacology, therapeutic use)
- Oligonucleotides, Antisense
(chemistry, metabolism, pharmacology, therapeutic use)
|